Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Clinical stage biopharmaceutical company Otonomy nets $107mm in IPO

Executive Summary

Otonomy Inc. (clinical-stage biopharma treating ear diseases) netted $107mm in its IPO on Nasdaq, pricing 7.2mm shares (including the overallotment) at $16 per share, the high end of the range. The company first filed in July, and in early August announced plans to sell 5.3mm shares at $14-16.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies